Work undertaken by the DSU in support of the ongoing technology appraisal of azacitidine (Vidaza, Celgene) is now available (dated December 2010). In the latest draft guidance, NICE recommends azacitidine as a treatment option for a sub-group of patients with myelodysplastic syndromes and related conditions. This decision is based on a revised patient access scheme and the application of the end-of-life guidance.
For further information, contact Paul Tappenden.
